Johnson A. TNF-induced activation of pulmonary microvessel endothelial cells: a role for GSK3␤.
␤-catenin is constitutively phosphorylated by GSK3␣/␤ (1, 3, 22) . Phosphorylation of ␤-catenin (Ser45, Ser37, Ser33, and Thr41) occurs within a multiprotein destruction complex composed of GSK3␤, axin, adenomatous polyposis coli (APC), and other putative partners (1, 3, 22) . Phosphorylated ␤-catenin is targeted for ubiquitination by ␤-transducin repeat containing protein (bTrCP) and degraded by the proteasome (1, 3, 22) . Conversely, the inhibition of GSK3␣/␤ is associated with suppressed phosphorylation and increased nuclear translocation of ␤-catenin.
TNF␣ is a mediator of sepsis syndrome and acute respiratory distress syndrome (9, 25, 31) . In pulmonary microvessel endothelial cells, this laboratory demonstrated TNF causes a PKC␣-mediated barrier dysfunction associated with dislocation of ␤-catenin from ␤-actin within the zonular adherence (10, 12, 18, 23) . Thus, the dislocation of ␤-catenin may result in genomic activity of ␤-catenin that can be modulated by GSK3␤ activity (1, 4, 5, 15, 25) . A role for GSK3␤ in modulating the nuclear activity of ␤-catenin in response to TNF in pulmonary microvessel endothelium is not known. Thus, we tested the hypothesis that PKC␣ activation causes inhibition of GSK3␤, which modulates the nuclear activity of ␤-catenin in response to TNF.
METHODS

Cell Culture
Rat (RLMVEC) and bovine (BLMVEC) lung microvessel endothelial cells were obtained at 4th passage (Vec Technologies, Rensselaer, NY) (6) . Preliminary studies showed that the TNF-induced responses of rat and bovine endothelium were similar using the protocols indicated below; thus, the data derived from the rat and bovine endothelium were combined. The preparations were identified by Vec Technologies as pure populations by 1) the characteristic "cobblestone" appearance as assessed by phase-contrast microscopy, 2) the presence of factor VIII-related antigen, 3) the uptake of acylated low-density lipoproteins, and 4) the absence of smooth muscle actin. RLMVEC were cultured from 6 to 10 passages in MCDB 131 complete medium (Vec Technologies) supplemented with 20% FBS (Hyclone, Hyclone Laboratories, Logan, UT). BLMVEC were cultured from 6 to 12 passages in DMEM (Gibco, Grand Island, NY) supplemented with 20% FBS, 15 g/ml Endothelial Cell Growth Supplement (Upstate Biotechnology, Lake Placid, NY), and 1% nonessential amino acids (Gibco-BRL). Both cell lines were maintained in 5% CO 2 plus humidified air at 37°C. A confluent pulmonary microvessel endothelial cell monolayer (PMEM) was reached within two to three population doublings, which took 3-4 days. For all studies, incubation of PMEM with reagents was performed with phenol-free DMEM (pf-DMEM, Gibco-BRL) to avoid any antioxidant effect of phenol. The pf-DMEM was supplemented with 10% FBS.
Reagents
All reagents were supplied by Sigma Chemical (St. Louis, MO) unless otherwise noted.
Highly purified recombinant human TNF␣ from Escherichia coli (endotoxin Ͻ0.1 ng/g) was obtained from American Research Products (Belmont, MA). PMEM were treated with TNF at 100 ng/ml (from a stock solution of 10 g/ml), a dose that induces a consistent permeability increase (13, 23) . Gö6976, a selective inhibitor of cPKC (26) , and SB-216763, a selective inhibitor of GSK3␤ that blocks the GSK3␤ binding site for ATP (3, 9) , were obtained from BIOMOL International (Plymouth Meeting, PA). LiCl 2 was used as a positive control for chemical inhibition of GSK3␤. PMEM were cotreated Ϯ TNF with Gö6976 (50 nM), SB-216763 (1 nM), or LiCl 2 (30 mM) following a 15-min pretreatment at the same concentrations.
Plasmids, siRNAs, and Transfections
Plasmids. Hemoagglutinin (HA)-tagged plasmids, human HA-GSK3␤ (wild type: wGSK3␤) and HA-GSK3␤ K85A (kinase dead: kdGSK3␤), ligated to CMV-driven pcDNA3 vectors (Addgene plasmids 14753 and 14755, developed by Dr. Woodgett, ref. 28) , were used to elucidate the role of GSK3␤ in the response to TNF (17, 28) . The kinase dead-GSK3␤ isoform is derived by the mutation within the catalytic site Lys85 and Lys86 to Meth85 and Ala86.
To measure ␤-catenin-dependent promoter activity, a luciferase reporter system was used. The TCF Reporter Plasmid Kit (Millipore, Temecula, CA) contains a TOPflash plasmid with two sets (1 set in the reverse orientation) of three copies of the TCF/␤-catenin-dependent binding sites driving a minimal thymidine kinase promoter to encode firefly luciferase (17) . A FOPflash plasmid with mutated binding sites was included in the kit and was used as a negative control.
Plasmid transfection. Transfection complex was formed by adding Targefect F2 (a nonlipid cationic polymer; Targeting Systems, Santee, CA) and Virofect (adenovirus-derived; Targeting Systems) to the plasmids in serum-free DMEM. A ratio of 1 g DNA/2 l Targefect F2 ϩ 5 l Virofect/ml DMEM was used to provide treatment concentrations of 1.5 g DNA/ml of media. Subconfluent PMEM in six-well plates were transfected with 1 ml of complex/well for 2 h, after which the complex and media were removed and replaced with normal growth medium, and the cells were incubated for 24 h until confluent.
siRNA. To examine PKC␣ mediation of GSK3␤ inhibition, PKC␣ depletion through RNA interference with siRNA was performed in RLMVEC. All double-stranded predesigned HPLC-grade siRNA oligos were obtained from Eurofins MWG Operon (Huntsville, AL). The following siRNA oligos were used: rat PKC␣ 1) AGAAGGCAACGUGGAACUCtt, rat PKC␣ 2) GGAGCCACAAGCAGUAUUCtt, and nonspecific control AGGUAGUGUAAUCGCCUUGtt.
siRNA transfection. Transfection of siRNAs was accomplished using the Targefect-siRNA transfection kit (Targeting Systems). Transfection complex was formed by adding 5 l of solution A and 10 l of solution B to 75 pmol siRNA/ml serum-free DMEM. Subconfluent PMEM in six-well plates were transfected with 1 ml of complex/well for 2 h, after which the complex and media were overlayed with normal growth medium. An additional identical transfection was performed 24 h later, and the cells were then incubated until 72 h postinitial transfection.
Subcellular Fractionation and Total Cell Lysates
PMEM were collected from 100 mM culture dishes using the CelLytic NuCLEAR Extraction Kit with modifications. All extraction and lysis buffers contained mammalian (1ϫ) protease inhibitor cocktail, phosphatase inhibitor cocktails 1 and 2 (1ϫ), and 0.1 mM DTT, and all processing was at 4°C. Before collection, treated PMEM were washed twice with ice-cold Dulbecco's PBS without ions (Gibco) containing 0.1 mM activated sodium orthovanadate. Cells were then scraped into 1.5-ml microtubes with 300 l of hypotonic lysis buffer (1ϫ HLB), disrupted by aspirating up and down 5ϫ through a 29-gauge needle on a 1-ml syringe, and then centrifuged at 1,500 g for 5 min. The supernatant was collected and separated into cytosolic and cell membrane fractions by centrifugation at 110,000 g for 1 h. The crude nuclear fraction from the initial centrifugation was resuspended in 250 l of HLB, disruption and centrifugation were repeated, and the supernatant was discarded. The nuclear pellet was next resuspended in 250 l of HLB containing 0.35% Igepal CA-630, vortexed for 10 s, and centrifuged at 11,000 g for 30 s. This final nuclear pellet was resuspended in 100 l of 1ϫ nuclear extraction buffer, shaken for 30 min, and centrifuged at 18,500 g for 7 min, and the supernatant was collected as nuclear proteins. The supernatant from the prior ultracentrifuged fraction was collected as cytosolic proteins, and the membrane pellet was washed briefly in HLB, dissolved in membrane lysis buffer (10 mM Tris ⅐ HCl, pH 7.5, 0.1% SDS, 0.5% Triton X-100, and 0.5% sodium deoxycholate), and the insoluble fractions were removed by centrifugation at 18,500 g for 30 min. The supernatant was collected as the cell membrane fraction.
To demonstrate successful cell fractionation, blots were probed with mouse monoclonal anti-tubulin (6A204, Santa Cruz), mouse monoclonal anti-CD31 (clone TLD-3A12; AbD SeroTec, Raleigh, NC), and goat polyclonal anti-lamin-A (Santa Cruz) for cytoplasmic, cell membrane, and nuclear markers, respectively. The acceptable quality of the cell fractions is indicated by the mean percent of total Ϯ SE of the following markers. The distribution of nuclear marker lamin-A is cytosol 3.5 Ϯ 1.0, membrane 11.6 Ϯ 1.8, and nucleus 84.8 Ϯ 2. Total cell lysates were collected from PMEM grown and treated in six-well culture plates by washing, as described above, and then lysing and scraping with 125 l/well membrane lysis buffer. Lysates were cleared by centrifugation at 18,500 g for 45 min. All cellular fraction and total cell lysate protein concentrations were determined by BCA assay (Pierce Biotechnology, Rockford, IL), and proteins in each group were normalized.
Immunoblots
Protein identification using PAGE-Western blot was done with adaptations of previously described techniques from this laboratory (12, 13, 23) . Equal quantities of cell lysates, 12-16 g/lane, were separated on either 8 -16% gradient or 7.5% single density 1.5-mmthick polyacrylamide minigels. Equal loading of proteins was confirmed in all blots following the final immunoprobe by stripping the blots, incubating with Bradford protein reagent, destaining with successive washes of a 50% methanol 1% acetic acid solution, and then comparing total protein densities between lanes as previously described (23) . The gels were transferred to PVDF membranes (Immobilon-P; Millipore, Bedford, MA), rinsed in TBS (10 mM Tris ⅐ HCl, pH 7.5, 100 mM NaCl), blocked in blotto plus phosphatase inhibitors (BPI) [TTBS: (TBS; 0.05% Tween 20), 5.0% wt/vol nonfat dry milk, 50 mM NaF, 0.1 mM activated Na 3VO4], and probed in a 1:2,000 dilution of rabbit polyclonal anti-phospho-GSK3␣/␤-Ser21/9 (Cell Signaling) according to the manufacturer's directions. Following five 5-min washes in TTBS, the blots were then incubated for 1.5 h at room temperature in BPI containing a mixture of goat anti-rabbit (Santa Cruz) and goat anti-biotin (Cell Signaling) horseradish peroxidase (HRP) conjugates diluted 1:5,000 each. After imaging, the blots were stripped with Restore Western Blot Stripping Buffer (Pierce), reblocked in BPI, washed, and incubated for 2 h at room temperature in TTBS ϩ 5% BSA containing mouse monoclonal anti-phospho-GSK3␣/␤-Tyr279/216 (clone 5G-2F, Millipore) diluted 1:2,500, followed by 1 h in BPI with the appropriate secondary antibodies. The blots were again stripped after imaging, reblocked, and reprobed in BPI with either a 1:2,000 dilution of rabbit polyclonal anti-␤-catenin (Santa Cruz) or a 1:5,000 dilution of mouse monoclonal anti-nonphosphorylated-␤-catenin (clone 8E4, Millipore), which binds only ␤-catenin with non-phosphorylated Ser33 and Ser37. The primary and secondary incubations for these immunoprobes were both at 37°C for 45 min each. For confirmation of transfect expression, blots were probed with either goat polyclonal anti-HA-HRP conjugate (Bethyl Laboratories, Montgomery, TX) or mouse monoclonal anti-luciferase (clone LUC-1, Sigma), diluted 1:5,000 each in BPI for 1 h at room temperature. Cruz Marker (Santa Cruz Biotechnology, Santa Cruz, CA) molecular weight standards and/or Biotinylated Protein Ladder (Cell Signaling Technology, Danvers, MA) were used for in-image molecular weight reference. Imaging substrates used were West Dura Extended Duration Substrate (Pierce; GSK3, luciferase, hemagglutinin) or Supersignal West Pico Chemiluminescent Substrate (Pierce; catenins). Images were acquired on a Kodak Image Station 440CF (Eastman Kodak, Rochester, NY) and analyzed for net band intensity using the ROI threshold method with Kodak 1D software.
Luciferase Assay
TOPflash and FOPflash transfected cells in six-well plates were harvested after treatments in 100 l/well Lysis Solution (Tropix PE Biosystems, Bedford, MA) containing anti-protease (1ϫ) and phosphatase-1 inhibitor cocktails and 0.5 mM DTT. Lysates cleared by centrifugation at 18,500 g for 30 min at 4°C were analyzed for protein content and normalized to 0.7 g/l. Luciferase activity was measured in 7 g lysate/well against 0.5-50 pg/well recombinant luciferase (Promega, Madison, WI) in 96-well white microplates (no. 3917; Corning Costar, Cambridge, MA) with Luciferase Assay Reagent (Promega) on a Wallac 1420 Victor2 multilabel counter (EG&G Wallac, Turku, Finland). Results were calculated to yield luciferase (pg)/total protein (g) and are reported as a ratio of TOPflash/ FOPflash for a given treatment.
Statistics
A one-way ANOVA was used to compare values among the treatments. If significance among treatments was noted, a post hoc multiple comparison test was done with a Bonferroni (parametricequal variance) test to determine significant differences among the groups (29) . A Student's t-test was performed when appropriate. Each PMEM well and flask represents a single experiment. All data are reported as means Ϯ SE. Significance was at P Ͻ 0.05. There are 5-10 samples per group in all studies.
RESULTS
TNF Causes the Phosphorylation of GSK3␣/␤
The literature implicates GSK3␣/␤ in the lung microvessel endothelial response to TNF (31, 32) ; therefore, the following experiments will demonstrate if TNF induces a change in the phosphorylation of GSK3␣/␤. Figure 1A (n Ն 5) is a representative Western blot of phospho-Ser21/Ser9-GSK3␣/␤ using lysate from the control and TNF group. Inactive GSK3␣/␤ is detected using anti-phospho-Ser21/Ser9-GSK3␣/␤ (i.e., GSK3␣-Ser21 and GSK3␤-Ser9). The blot shows phospho-GSK3␣-Ser21 and phospho-GSK3␤-Ser9 at the expected molecular weight of the modified isoforms. Figure 1B (n Ն 5) demonstrates mean lysate phospho-GSK3␣-Ser21 and phospho-GSK3␣-Ser9 for the control and TNF group. In the TNF-4.0-h group, there was an insignificant increase in the phospho-GSK3␣-Ser21 but a significant increase in phospho-GSK3␤-Ser9 compared with the control group. In addition, the same blots were stripped and reprobed for phospho-GSK3␣-Tyr279 and phospho-GSK3␤-Tyr216 indicating insignificant decreases in the TNF group compared with the control group (Table 1) . Finally, the same blots were stripped and reprobed for native GSK3␤ indicating no significant affect on native GSK3␤ expression between the control and TNF group (control 83,467 Ϯ 6,624 relative density units vs. TNF 69,348 Ϯ 7,539 relative density units). In separate studies, the PMEM were treated with TNF-0.5 h, which showed no significant change in the phospho-GSK3␤-Ser9, compared with the control group (control 7,857 Ϯ 687 relative density units vs. TNF 7,689 Ϯ 367 relative density units). Figure 1C (n Ն 5) demonstrates mean compartmentalized phospho-GSK3␤-Ser9 for the control and TNF group. In the TNF-4.0-h group, the increased phospho-GSK3␤-Ser9 is in the cytoplasm, and, interestingly, in the nuclear compartment of the PMEM. The data of Fig. 1 show that TNF induces the phosphorylation of GSK3␤-Ser9, an indication of decreased activity of GSK3␤ in response to TNF.
PKC␣ Causes the Phosphorylation of GSK3␤
PKC modulates GSK3␤ phosphorylation in different cell types; however, the role of PKC␣ in TNF-induced GSK3␤ phosphorylation in lung microvessel endothelial cells is not known (4). The following experiments will test the idea that PKC␣ modulates the phosphorylation of GSK3␤. Figure 2A (n Ն 5) demonstrates mean lysate phospho-GSK3␤-Ser9 for the control and Gö6976 Ϯ TNF groups. In the TNF-4.0-h group, there is an increase in the phospho-GSK3␤-Ser9 compared with the control group. In the Gö6976 ϩ TNF group, there is no change in the phospho-GSK3␤-Ser9 compared with the Gö6976 group. Table 2 shows the PKC␣ protein levels in the control, nonsense-RNA, and siRNA-PKC␣ groups with and without TNF. In the siRNA-PKC␣ Ϯ TNF groups, there is a significant depletion of PKC␣ protein compared with the respective control and nonsense-RNA groups. In the TNF and nonsense-RNA ϩ TNF groups, the PKC␣ protein was less than in the respective control and nonsense-RNA groups. Figure 2B (n Ն 5) demonstrates lysate phospho-GSK3␤-Ser9 vs. the PKC␣ protein levels in the control, nonsense-RNA, and siRNA-PKC␣ groups with and without TNF. In the control, nonsense-RNA, and siRNA-PKC␣ groups, there is no correlation between phospho-GSK3␤-Ser9 vs. the PKC␣ protein levels. In the TNF, nonsense-RNA ϩ TNF, and siRNA-PKC␣ ϩ TNF groups, the increase in phospho-GSK3␤-Ser9 positively correlates y ϭ 10,204(x)/[25,912 ϩ x] (P ϭ 0.0126) with increasing PKC␣ protein. The data of Fig. 2 support the idea that TNF induces the phosphorylation of GSK3␤-Ser9, which is modulated by PKC␣.
TNF Induces Increased Unphospo-␤-Catenin-Ser33/Ser37 That Is Mediated By GSK3␤
␤-catenin is a primary target for GSK3␤-mediated phosphorylation; therefore, the purpose of the next series of experiments is to prove that the TNF-induced inhibition of GSK3␤ is associated with increased unphospo-␤-catenin-Ser33/Ser37 in the pulmonary microvessel endothelium. Figure 3 (n Ն 5) demonstrates mean total lysate unphospo-␤-catenin-Ser33/Ser37 and the associated nuclear/cytosol ratio in the control and TNF group. In the TNF-4.0-h group, there is increased total and nuclear/cytosol ratio of unphospo-␤-catenin-Ser33/Ser37 compared with the control group. The data indicate that TNF causes an increase in the nuclear translocation of unphospo-␤-catenin-Ser33/Ser37. Figure 4A (n Ն 5) demonstrates mean total lysate unphospo-␤-catenin-Ser33/Ser37 in the control and SB-216763 groups with and without treatment with TNF. In the TNF and SB-216763 group, there is increased unphospo-␤-catenin-Ser33/ Ser37 compared with the control group. In the SB-216763 group, the unphospo-␤-catenin-Ser33/Ser37 was similar to the value in the SB-216763 ϩ TNF and TNF groups. In the lithium-treated group, there was increased unphospo-␤-catenin-Ser33/Ser37 compared with the control group, which verified GSK␤ dependence for unphospo-␤-catenin-Ser33/Ser37. Figure 4B (n Ն 5) is a representative Western blot for detection of HA using lysate from the control, wGSKK3␤, and kd-GSK3␤ groups with and without TNF treatment. The blot shows similar increases in the HA, based on the expected molecular weight, in the GSK3␤ groups with and without TNF treatment. The same blot was stripped and reprobed for GSK3␤ indicating that transfection had no affect on the native GSK3␤ expression and equally increased the wGSKK3␤ and kd-GSK3␤ to 5ϫ the native GSK3␤ level (data not shown). Figure 4C (n Ն 5) demonstrates, in separate studies, mean total lysate unphospo-␤-catenin-Ser33/Ser37 in the wGSK3␤ (i.e., activity repletion) and kdGSK3␤ (i.e., activity inhibition) groups with and without treatment with TNF. In the wGSK3␤ ϩ TNF group, there is no change in unphospo-␤-catenin-Ser33/Ser37 compared with the wGSK3␤ group. In the kdGSK3␤ group, there is increased unphospo-␤-catenin-Ser33/Ser37 compared with the wGSK3␤ group. In the kdGSK3␤ group, the unphospo-␤-catenin-Ser33/Ser37 was similar compared with the kdGSK3␤ ϩ TNF group, and greater than the value in the wGSK3␤ ϩ TNF group. The data indicate that TNF causes an increase in unphospo-␤-catenin-Ser33/Ser37 that is mediated by inhibition of GSK3␤.
The purpose of the following protocols is to test the idea that the increase in unphospo-␤-catenin-Ser33/Ser37 is due to a TNF-induced increase in the total ␤-catenin. Figure 5A (n Ն 5) demonstrates mean total lysate ␤-catenin (i.e., using an antibody against an idiotype sequence distal to the ␤-catenin phosphorylation sites Ser33/Ser37) and the associated nuclear/ cytosol ratio in the control and TNF groups. In the TNF-4.0-h group, there is no change total ␤-catenin compared with the control group; however, there is an increased total ␤-catenin nuclear/cytosol ratio compared with the control group.
Figure 5B shows, in separate studies, the ␤-catenin in the control and SB-216763 Ϯ TNF groups. In the control ϩ TNF and SB-216763 ϩ TNF groups, there is no change in ␤-catenin compared with the respective control and SB-216763 groups. Figure 5C shows (n Ն 4), in separate studies, total lysate ␤-catenin in the wGSK3␤ and kdGSK3␤ groups with and without TNF treatment. In the wGSK3␤ ϩ TNF and kdGSK3␤ ϩ TNF groups, Fig. 2 . PKC␣ mediates phosphorylation of GSK3␤-Ser9. A: mean data of phospho-GSK3␤-Ser9 in the control and Gö6976 groups with and without TNF. B: data of phospho-GSK3␤-Ser9 vs. PKC␣ protein in the control, nonsense-RNA, siRNA groups with and without TNF. *Different (P Ͻ 0.05) from the control group using an unpaired t-test. there is no change in total ␤-catenin compared with the respective wGSK3␤ and kdGSK3␤ groups. The data support the idea that the TNF-induced increase in unphospo-␤-catenin-Ser33/Ser37 is because of a decrease in the phosphorylation of an unchanged total pool of ␤-catenin, rather than due to the constitutive phosphorylation of an increased total pool of ␤-catenin.
TNF Induces Increased ␤-Catenin-Dependent Promoter Activity Mediated By GSK3␤
The purpose of the following experiments is to show that an outcome of TNF-induced phosphorylation of GSK3␤ and increased unphospo-␤-catenin-Ser33/Ser37 is altered activity of ␤-catenin-dependent promoter activity. Figure 6A (n Ն 5) is a representative Western blot demonstrating the luciferase protein for the control and TNF group. The blot shows TOPflash plasmid transfection causes expression of luciferase protein based on the expected molecular weight. Figure 6B (n Ն 5) demonstrates the TOPflash/FOPflash luciferase activity ratio in the control, SB-216763, wGSK3␤, and kdGSK3␤ groups with and without treatment with TNF. FOPflash (i.e., mutant consensus sequence for ␤-catenin-dependent activity) is used to correct for ␤-catenin-independent expression and transfection efficiency. In the TNF and SB-216763 group, there is increased TOPflash/FOPflash luciferase activity ratio compared with the control group. In the SB-216763 group, the TOPflash/ FOPflash luciferase activity ratio is similar to the value in the SB-216763 ϩ TNF and TNF groups. In separate studies, Fig. 6B demonstrates the mean TOPflash/FOPflash luciferase activity ratio in the wGSK3␤ and kdGSK3␤ groups with and without treatment with TNF. In the wGSK3␤ ϩ TNF group, the TOPflash/ FOPflash luciferase activity ratio is similar to the value in the wGSK3␤ group. In the kdGSK3␤ group, there is increased TOPflash/FOPflash luciferase activity ratio compared with the wGSK3␤ group. In the kdGSK3␤ group, the TOPflash/FOPflash luciferase activity ratio is similar to the value in the kdGSK3␤ ϩ TNF group and greater than the value in the wGSK3␤ ϩ TNF group. The data of Fig. 6 support the notion that an outcome of TNF-induced phosphorylation of GSK3␤ and increased unphospo-␤-catenin-Ser33/Ser37 is altered activity of ␤-catenindependent promoter activity.
DISCUSSION
The present data indicate the novel finding, in pulmonary microvessel endothelium, that TNF causes phosphorylation of Fig. 4 . GSK3␤ suppression mediates the TNF-induced increase in unphospho-␤-catenin-Ser33/37. A: mean (n Ն 5) total lysate unphospho-␤-catenin-Ser33/37 in the control, LiCl2, and SB-216763 groups with and without TNF. B: representative Western blot (n Ն 5) demonstrates the hemoagglutinin protein of the different GSK3␤-plasmid groups with and without TNF. C: mean (n Ն 5) total lysate unphospho-␤-catenin-Ser33/37 in the different GSK3␤-plasmid groups with and without TNF. #Different (P Ͻ 0.05) from the wGSK3␤ group using an ANOVA with Bonferroni post hoc multiple comparison test; *different (P Ͻ 0.05) from the control group using an ANOVA with Bonferroni post hoc multiple comparison test.
GSK3␤-Ser9, an indicator of GSK3␤ inhibition, which is modulated by PKC␣. In addition, the present study supports the theory that TNF induces an increase in unphospho-␤-catenin-Ser33/37, which is modulated by inhibition of GSK3␤ because of the following facts. First, the TNF-induced increase in the GSK3␤-Ser9 directly correlates with the enhanced unphospho-␤-catenin-Ser33/37. Second, in the kdGSK3␤ and SB-216763 groups, there is increased unphospho-␤-cateninSer33/37 compared with the respective wGSK3␤ and control groups. In the kdGSK3␤ plasmid, the mutation of Lys85 and Lys86 to Meth85 and Ala86 inhibits the catalytic site, thereby preventing GSK3␤-dependent phosphorylation (28) . Third, in the GSK3␤-inhibited groups (i.e., kdGSK3␤ and SB-216763), the level of unphospho-␤-catenin-Ser33/37 was similar to the TNF group. Fourth, in the GSK3␤-inhibited groups, there was no further TNF-induced increase in unphospho-␤-cateninSer33/37. Fifth, in the wGSK3␤ ϩ TNF group, there was no increase in unphospho-␤-catenin-Ser33/37 compared with the wGSK3␤ group, which was less than the values in the TNF, kdGSK3␤ ϩ TNF, and SB-216763 ϩ TNF groups. The repletion of GSK3␤ activity using wGSK3␤ assumes that the phosphorylation-mediated inhibition of GSK3␤ is substrate limited, reaching an asymptote within the concentration range of the expressed wGSK3␤. The dose of 1.5 g/ml for wGSK3␤ was chosen based on preliminary studies indicating that a lower dose of 1.0 g/ml for wGSK3␤ did not prevent the TNF-induced increase in unphosphorylated ␤-catenin. Importantly, the present study shows that the dose of 1.5 g/ml for wGSK3␤ consistently prevented the increase in unphosphorylated ␤-catenin. Finally, the positive control lithium chloride, a classic inhibitor of GSK3␤, caused an increase in the unphospho-␤-catenin-Ser33/37 (3). The effect of GSK3␤ plasmid transfection on the response to TNF is specific to the GSK3␤ isoform, rather than transfection, because of the different Fig. 5 . TNF induces an increase in nuclear translocation of total ␤-catenin. A: mean (n Ն 5) total lysate ␤-catenin and associated nucleus/cytoplasm ratio, derived from the immunoblots, for the control and TNF group. B: mean total lysate ␤-catenin for the SB-216763 Ϯ TNF group. C: mean (n Ն 5) total lysate ␤-catenin for the GSK3␤-plasmid isotypes with and without TNF. *Different (P Ͻ 0.05) from the control group using an unpaired t-test.
TNF-mediated outcomes between the similarly constructed wild-type and inactive GSK3␤ plasmids. Interestingly, TNF induced an insignificant increase in GSK3␣-Ser21 and an insignificant decrease in phosphorylation of GSK3␣-Tyr279 and GSK3␤-Tyr216, an indication of complex and possibly time-dependent mechanisms for further reductions in GSK3␣/ ␤ activity.
In the present study, the TNF-induced increase in phosphorylation of GSK3␤-Ser9 was inhibited by Gö6976, an inhibitor of the classic isoforms PKC␣, PKC␤, and PKC␥ (26) . It is known that PKC can alter the phosphorylation of GSK3␤ in other cell types (1, 4, 22) . This laboratory previously showed that antisense-PKC␣ prevents the TNF-induced alterations in endothelial barrier function (12) . A limitation with the use of antisense/siRNA is the inability to completely deplete the target protein without inducing untoward events. We could not completely deplete PKC␣, which is similar to our previous study, but discovered the important direct correlation of phospho-GSK3␤-Ser9 (i.e., dependent variable) with PKC␣ protein levels (i.e., independent variable). The correlation occurred only among the TNF groups and not in the similarly treated groups without the TNF. The use of this regression y ϭ 10,204(x)/[25,912 ϩ x] is the result of determining the best fit for the significance of the relationship between PKC␣ and phospho-GSK3␤-Ser9, which infers that the relationship of PKC␣ with phospho-GSK3␤-Ser9 is characteristic of ligand binding. The formula indicates that in the range of PKC␣ protein (i.e., 10,000 -60,000 relative density units) there is a TNF-induced functional association between PKC␣ and GSK3␤-Ser9, which supports the previous data that TNF activates PKC␣ in bovine lung arterial endothelium (12) . PKC␣ may directly phosphorylate GSK3␤ or modulate other events including control of Akt activity, which can phosphorylate GSK3␤ (3, 11, 22, 25, 28) .
Presently, in the rat lung microvessel endothelium, TNF causes a decrease in PKC␣ protein that contrasts with our previous data in bovine lung microvessel endothelium showing an increase in PKC␣ protein at TNF-4.0 h (27) . Activated PKC␣ is degraded by calpains, a noted mechanism for a decrease in PKC␣ (27) . Importantly, the PKC␣ inhibitors siRNA-PKC␣ and Gö6976 prevent the effect of TNF, despite the differential affect of TNF on the PKC␣ protein. We previously showed that PKC and/or PKC␣ mediates TNFinduced increases in superoxide, peroxynitrite, lung vasocontriction, edema, and endothelial permeability, events that can be linked to GSK3␤ (25, 27) .
In the present study, TNF induced an increase in the ␤-catenin-dependent TOPflash/FOPflash activity ratio indicating enhanced genomic activity of ␤-catenin (17) . Similarly, other inflammatory mediators, such as histamine and thrombin, increase the nuclear translocation of ␤-catenin that is correlated with the increased activity of the ␤-catenin-sensitive promoterreport construct TOPflash (2, 16). The TNF-induced increase in the TOPflash activity is dependent on the suppression of GSK3␤ activity because in the kdGSK3␤ and SB-216763 groups 1) there was increased TOPflash/FOPflash activity ratio compared with the control group, 2) the TOPflash/FOPflash ratio was similar to the TNF group, and 3) TNF did not induce a further increase in the TOPflash/FOPflash ratio. The efficacy of SB-216763 and kdGSK3␤ for decreasing GSK3␤ activity, as noted above, is supported by the increased unphosphorylated ␤-catenin-Ser33/37 in the SB-216763 and kdGSK3␤ groups. In addition, in the wGSK3␤ ϩ TNF group, the competitive inhibition of the TNF-induced increase in the TOPflash/ FOPflash ratio can be explained by the prevention of the increase in unphosphorylated ␤-catenin as indicated above. The TOPflash/FOPflash ratio represents ␤-catenin-dependent TCF-transcriptional activity because the FOPflash vector, by not having active ␤-catenin/TCF-consensus binding sites, corrects for nonspecific transfection events (11, 17) .
Nuclear ␤-catenin, via the interaction with transcription factors TCF, LEF-1, and other putative partners, can alter activity of the promoter region of genes such as cyclooxygenase, iNOS, and VE-cadherin (7, 8, 14, 16, 20, 24, 30) . Importantly, inflammatory mediators such as cyclooxygenase, iNOS, and VE-cadherin are within the paradigm for TNF-induced vascular injury; therefore, ␤-catenin-dependent transcription activity may indeed impact on pulmonary vascular injury (7, 8, Fig. 6 . GSK3␤ mediates the TNF-induced increase in ␤-catenin-dependent promoter activity. A: representative Western blot (n Ն 5) demonstrates the luciferase protein in the control and TNF group. B: mean (n Ն 5) lysate TOPflash/FOPflash luciferase activity ratio for the SB-216763 and GSK3␤-plasmid isotypes with and without TNF. *Different (P Ͻ 0.05) from the control group using an ANOVA with Bonferroni post hoc multiple comparison test. 14, 16, 20, 21, 24, 25, 27, 30) . In addition, GSK3␤ has myriad targeted effects that can impact on TNF-induced endothelial injury. GSK3␤ causes the phosphorylation of mitogen-activated protein kinases including c-Jun NH 2 -teminal kinase and p44/p42 mitogen-activated kinase (19, 20) . GSK3␤ mediates both activation and inhibition of the NF-B, a transcription factor that promotes TNF-induced lung injury (32) .
In the present study, TNF induced an increase in phospho-GSK3␤-Ser9 in the cytoplasm and in the nucleus. The marker analyses indicate that the increase in phospho-GSK3␤-Ser9 and unphosphorylated-␤-catenin-Ser37/33 in the cytosol is not due to significant nuclear/membrane contamination: nuclear-lamin-A in cytosol is 3.5 Ϯ 1.0%, and membrane CD31 in cytosol is 0.0 ϩ 0.0%. In addition, the marker analyses indicate that the increase in unphosphorylated-␤-catenin-Ser37/33 and phospho-GSK3␤-Ser9 in the nucleus is not due to cytosol/membrane contamination: cytosol-␤-tubulin in the nucleus is 0.05 Ϯ 0.02%, and membrane-CD31 in the nucleus is 0.0 ϩ 0.0%. The increase in the nuclear phospho-GSK3␤-Ser9 is consistent with GSK3␤ activity mediating phosphorylation and activity of transcription factors (3, 10, 17) ; thus, the effect of TNFinduced nuclear GSK3␤ on endothelial activation requires further investigation. Our data are partly dissimilar to the data of Eto et al. (10) that showed, in endothelial cells, TNF-0.5 h causes decreased phosphorylation of GSK3␤-Ser9. We used rat microvessel cells and 100 ng/ml TNF, whereas Eto et al. used human umbilical vein and aortic endothelial cells with a dose of 10 ng/ml TNF (10). However, similar to our data, Eto et al. also showed that TNF induces an increase in phospho-GSK3␤-Ser9 by TNF-4.0 (10).
In summary, TNF causes phosphorylation (i.e., inhibition) of GSK3␤ modulated by PKC␣. The phosphorylation of GSK3␤ results in enhanced ␤-catenin-dependent promoter activity. In lung microvessel endothelial cells, these novel findings show a link between TNF, PKC␣, GSK3␤, and ␤-catenin-dependent transcription activity, a known pathway in carcinogenesis. The development of strategies that target GSK3␤ may provide novel directions for therapy of lung vascular inflammation and correlated events such as cancer.
